ALMS
Alumis Inc. Common Stock NASDAQ$25.25
Mkt Cap $3.1B
52w Low $2.76
80.8% of range
52w High $30.60
50d MA $25.29
200d MA $13.62
P/E (TTM)
-8.8x
EV/EBITDA
-19.5x
P/B
71.1x
Debt/Equity
0.1x
ROE
-80.8%
P/FCF
-22.4x
RSI (14)
—
ATR (14)
—
Beta
-0.61
50d MA
$25.29
200d MA
$13.62
Avg Volume
1.5M
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflamm…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.97 | -0.95 | +2.1% | 25.38 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% | — |
| Nov 13, 2025 | AMC | -0.92 | -1.06 | -15.2% | 5.28 | -10.0% | +4.5% | +5.7% | +21.4% | +24.4% | +31.1% | — |
| Aug 13, 2025 | AMC | -1.11 | -1.17 | -5.4% | 4.42 | -5.9% | -0.7% | +7.5% | +9.7% | +7.0% | -0.2% | — |
| May 14, 2025 | AMC | -1.47 | -1.82 | -23.8% | 4.51 | -0.4% | +18.6% | +24.6% | +31.9% | +8.2% | +6.0% | — |
| Mar 19, 2025 | AMC | -1.40 | -0.23 | +83.6% | 4.37 | -2.1% | -18.3% | -14.2% | -13.5% | -8.5% | +12.6% | — |
| Nov 13, 2024 | AMC | -1.64 | -1.73 | -5.5% | 10.81 | +1.0% | -13.0% | -18.1% | -20.1% | -4.3% | -10.8% | — |
| Aug 13, 2024 | AMC | -4.50 | -23.10 | -413.3% | 12.54 | -2.3% | +1.4% | +2.6% | +2.1% | +3.7% | +3.7% | — |
| Mar 31, 2024 | AMC | — | -0.96 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -4.50 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -1.13 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $25.38 | $24.84 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% |
| Mar 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.38 | $24.84 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.18 | $18.50 | +1.8% | +7.6% | +16.0% | +21.6% | +33.9% | +32.9% |
| Jan 7 | Guggenheim | Maintains | Buy → Buy | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.31 | $22.20 | +167.1% | +95.3% | +115.6% | +118.8% | +135.4% | +153.8% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ALMS is adding standard forward-looking statement disclaimers to protect against litigation, suggesting management expects continued uncertainty or competitive pressures ahead.
Mar 30
8-K
Unknown — 8-K Filing
Alumis' Phase 3 validation of envudeucitinib for psoriasis represents a major de-risking event that could drive significant upside if FDA approval proceeds, making this a pivotal inflection point for the stock.
Mar 19
Data updated apr 24, 2026 5:25pm
· Source: massive.com